860 related articles for article (PubMed ID: 24191305)
1. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
[TBL] [Abstract][Full Text] [Related]
2. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.
Mann JF; Schmieder RE; McQueen M; Dyal L; Schumacher H; Pogue J; Wang X; Maggioni A; Budaj A; Chaithiraphan S; Dickstein K; Keltai M; Metsärinne K; Oto A; Parkhomenko A; Piegas LS; Svendsen TL; Teo KK; Yusuf S;
Lancet; 2008 Aug; 372(9638):547-53. PubMed ID: 18707986
[TBL] [Abstract][Full Text] [Related]
3. Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?
Serebruany VL; Atar D; Hanley DF
Cerebrovasc Dis; 2008; 26(5):563-4. PubMed ID: 18936537
[No Abstract] [Full Text] [Related]
4. Telmisartan, ramipril, or both in patients at high risk for vascular events.
; Yusuf S; Teo KK; Pogue J; Dyal L; Copland I; Schumacher H; Dagenais G; Sleight P; Anderson C
N Engl J Med; 2008 Apr; 358(15):1547-59. PubMed ID: 18378520
[TBL] [Abstract][Full Text] [Related]
5. ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.
Schindler C
Ther Adv Cardiovasc Dis; 2008 Aug; 2(4):233-48. PubMed ID: 19124424
[TBL] [Abstract][Full Text] [Related]
6. No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.
Han SW; Won YW; Yi JH; Kim HJ
Nephrol Dial Transplant; 2007 Apr; 22(4):1150-5. PubMed ID: 17255126
[TBL] [Abstract][Full Text] [Related]
7. Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.
Zimmermann M; Unger T
Expert Opin Pharmacother; 2004 May; 5(5):1201-8. PubMed ID: 15155118
[TBL] [Abstract][Full Text] [Related]
8. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials.
Teo K; Yusuf S; Sleight P; Anderson C; Mookadam F; Ramos B; Hilbrich L; Pogue J; Schumacher H;
Am Heart J; 2004 Jul; 148(1):52-61. PubMed ID: 15215792
[TBL] [Abstract][Full Text] [Related]
9. ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?
Oparil S; Kjeldsen SE; Hedner T; Narkiewicz K
Blood Press; 2009; 18(1-2):4-6. PubMed ID: 19191085
[No Abstract] [Full Text] [Related]
10. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
Weir MR
Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
[TBL] [Abstract][Full Text] [Related]
11. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
Unger T
Am J Cardiol; 2003 May; 91(10A):28G-34G. PubMed ID: 12781906
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin II receptor antagonists and heart failure: angiotensin-converting-enzyme inhibitors remain the first-line option.
Prescrire Int; 2005 Oct; 14(79):180-6. PubMed ID: 16285075
[TBL] [Abstract][Full Text] [Related]
13. The sudden demise of dual renin-angiotensin system blockade or the soft science of the surrogate end point.
Messerli FH
J Am Coll Cardiol; 2009 Feb; 53(6):468-70. PubMed ID: 19195602
[TBL] [Abstract][Full Text] [Related]
14. Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study.
Mann JF; Yi QL; Sleight P; Dagenais GR; Gerstein HC; Lonn EM; Bosch J;
Clin Nephrol; 2005 Mar; 63(3):181-7. PubMed ID: 15786818
[TBL] [Abstract][Full Text] [Related]
15. Dual blockade of the renin-angiotensin-aldosterone system with high-dose angiotensin-converting enzyme inhibitor for nephroprotection: an open, controlled, randomized study.
Tylicki L; Renke M; Rutkowski P; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Scand J Urol Nephrol; 2008; 42(4):381-8. PubMed ID: 19230172
[TBL] [Abstract][Full Text] [Related]
16. Recent advances in cardiovascular risk reduction: implications of ONTARGET.
Guthrie R
Clin Cornerstone; 2009; 9 Suppl 3():S18-26. PubMed ID: 19409352
[TBL] [Abstract][Full Text] [Related]
17. The ONTARGET/TRANSCEND Trial Programme: baseline data.
Sleight P
Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
[TBL] [Abstract][Full Text] [Related]
18. Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND).
Böhm M; Baumhäkel M; Probstfield JL; Schmieder R; Yusuf S; Zhao F; Koon T;
Am Heart J; 2007 Jul; 154(1):94-101. PubMed ID: 17584560
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.
Sharma A; Baliga V;
J Indian Med Assoc; 2008 Mar; 106(3):191-4, 196. PubMed ID: 18712142
[TBL] [Abstract][Full Text] [Related]
20. Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.
Williams B; Lacourcière Y; Schumacher H; Gosse P; Neutel JM
J Hum Hypertens; 2009 Sep; 23(9):610-9. PubMed ID: 19225530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
